Transaction #17427 · Form 4 · 0001584516-25-000009
ZEVRA THERAPEUTICS, INC. · Stock award · Stock Option (right to buy)
ZEVRA THERAPEUTICS, INC. · Transacted December 2, 2025 · Filed December 9, 2025
What does this filing report?
An SEC Form 4 filing for ZEVRA THERAPEUTICS, INC. records a stock award involving Stock Option (right to buy) on December 2, 2025. The reported quantity was 45,000. The filing date is December 9, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- ZEVRA THERAPEUTICS, INC.
- Company CIK
- 0001434647
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 45,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 45,000
- Ownership description
- Not reported
- SEC acceptance time
- Dec 9, 2025, 4:18 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Secor Alicia ↗
Director
CIK 0001584516
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 45,000
- Conversion / exercise price
- 8.17
- Exercise date
- Not reported
- Expiration date
- December 1, 2035
Filing footnotes & remarks
- F1
- The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, December 2, 2025.
- F2
- The option will vest and become exercisable as follows: (1) in three equal installments on the each of the dates that are one day prior to the first three annual stockholder meetings occurring after the grant date, or (2) immediately prior to a Change in Control, subject in each case to the director's continued service on such vesting date.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.